{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:47:15Z","timestamp":1792928835722,"version":"4.5.0"},"reference-count":9,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Data on the association between chimeric antigen receptor (CAR)-T-cell kinetics and patient outcome in the nontrial setting are missing, mainly due to the lack of broadly available CAR-T-cell diagnostic quantification tools. We performed prospective quantification of axicabtagene ciloleucel (axi-cel) in 21 patients treated for aggressive B-cell lymphoma at our clinic. Median peak CAR-T-cell count was 16.14 CAR-T cells\/\u00b5L. Patients with 16.14\/\u03bcL or higher peak CAR-T cells (strong expanders) had more day-30 objective responses (91% vs 40%, P = .02). In univariate analysis, peak CAR-T cell \u2265 16.14 (P &amp;lt; .001), normal platelet counts at start of lymphodepletion (P &amp;lt; .001), no prior stem cell transplant (P = .04), and peak CAR-T cells as continuous variable (P = .03) were associated with better progression-free survival (PFS). After adjusting for platelet counts and prior stem cell transplantation, peak CAR-T cells below median was still associated with shorter PFS (relative risk, 0.15, 95% confidence interval, 0.04-0.59, P = .007). Low platelet counts also maintained significant impact on PFS. Our data demonstrate association of axi-cel levels and outcome in a nontrial setting and for the first time use a cutoff to segregate weak and strong expanders with respective outcomes.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003959","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T16:28:32Z","timestamp":1623169712000},"page":"2523-2527","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting"],"prefix":"10.1182","volume":"5","author":[{"given":"Francis A.","family":"Ayuk","sequence":"first","affiliation":[{"name":"1Department of Stem Cell Transplantation;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Berger","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Badbaran","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Zabelina","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Sonntag","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9050-6766","authenticated-orcid":false,"given":"Kristoffer","family":"Riecken","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Geffken","sequence":"additional","affiliation":[{"name":"2Institute for Transfusion Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4334-7640","authenticated-orcid":false,"given":"Dominic","family":"Wichmann","sequence":"additional","affiliation":[{"name":"3Department of Intensive Care Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Frenzel","sequence":"additional","affiliation":[{"name":"4Department of Hematology and Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenther","family":"Thayssen","sequence":"additional","affiliation":[{"name":"5Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Zeschke","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9780-7211","authenticated-orcid":false,"given":"Boris","family":"Fehse","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"issue":"26","key":"2022062219531446800_B1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"issue":"1","key":"2022062219531446800_B2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med."},{"issue":"19","key":"2022062219531446800_B3","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv."},{"issue":"27","key":"2022062219531446800_B4","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol."},{"issue":"27","key":"2022062219531446800_B5","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol."},{"key":"2022062219531446800_B6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.omtm.2019.12.018","article-title":"Digital PCR assays for precise quantification of CD19-CAR-T cells after treatment with axicabtagene ciloleucel","volume":"16","author":"Fehse","year":"2020","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"7","key":"2022062219531446800_B7","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3390\/cancers12071970","article-title":"Accurate in-vivo quantification of CD19 CAR-T cells after treatment with axicabtagene ciloleucel (Axi-Cel) and tisagenlecleucel (Tisa-cel) using digital PCR","volume":"12","author":"Badbaran","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"27","key":"2022062219531446800_B8","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022062219531446800_B9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2022008370","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/11\/2523\/1903965\/advancesadv2020003959.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/11\/2523\/1903965\/advancesadv2020003959.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T19:53:55Z","timestamp":1655927635000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/11\/2523\/476051\/Axicabtagene-ciloleucel-in-vivo-expansion-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,6,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003959","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2022008370","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]}}}